Effects of Ocrelizumab on Dental Pulp Derived Mesenchymal Stem Cells

Belma Akpinar Yilmaz; Cuneyt Aki

doi:10.36948/ijfmr.2022.v04i06.1259

Effects of Ocrelizumab on Dental Pulp Derived Mesenchymal Stem Cells

Author(s)	Belma Akpinar Yilmaz, Cuneyt Aki
Country	Turkey
Abstract	Multiple sclerosis (MS) is a chronic autoimmune central nervous system (CNS) disease characterized by inflammation, demyelination and axonal damage. The most important goal in MS treatment is to provide neuroregeneration. However, current treatments only work to slow the progression of MS. Ocrelizumab is a humanized anti-CD20 monoclonal antibody used in the treatment of MS. In this study, it was aimed to investigate the effects of Ocrelizumab on the proliferation and differentiation potential of dental pulp-derived stem cells (DP-SC). For this purpose, three different (1.5 µg/mL, 15 µg/mL and 150 µg/mL) doses of Ocrelizumab were added to the normal culture medium, and then proliferation analyzes at 24, 48 and 72 hours were performed with the WST-1 assay. Ocrelizumab treatment for 24 and 48 hours was observed to dose-dependently reduce the proliferation of stem cells. At 72 hours, the efficacy of the drug on proliferation was lost at low doses. Similarly, a dose-dependent decrease in the expression of stemness marker, Rex1, was detected. The expression of the adipogenic differentiation marker ADFP, osteogenic differentiation marker RUNX2, chondrogenic differentiation marker SOX9, and neurogenic differentiation marker TUBB3 were evaluated to determine the influence on the differentiation potential of stem cells under the drug effect. While RUNX2, SOX9 and TUBB3 expressions increased in a dose-dependent manner, there was a decrease in ADFP expression in parallel to the drug dose. According to the results of the study, ocrelizumab might have the potential to support the regenerative effects by supporting the differentiation of DP-SCs in osteogenic, chodrogenic and neurogenic.
Keywords	Multiple Sclerosis, Mesenchymal Stem Cell, Ocrelizumab, Cell Differentiation
Field	Medical / Pharmacy
Published In	Volume 4, Issue 6, November-December 2022
Published On	2022-12-29
Cite This	Effects of Ocrelizumab on Dental Pulp Derived Mesenchymal Stem Cells - Belma Akpinar Yilmaz, Cuneyt Aki - IJFMR Volume 4, Issue 6, November-December 2022. DOI 10.36948/ijfmr.2022.v04i06.1259
DOI	https://doi.org/10.36948/ijfmr.2022.v04i06.1259
Short DOI	https://doi.org/grkbwn

View / Download PDF File

E-ISSN 2582-2160

doi

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads

Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 6 Isu 6 Cover Page Vol 6 Isu 5 Cover Page Vol 6 Isu 4

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9898-5948-55	editor@ijfmr.com

International Journal For Multidisciplinary Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Effects of Ocrelizumab on Dental Pulp Derived Mesenchymal Stem Cells

Share this